Kinder Morgan, Inc.
$101.86B- Market cap
- $69.92B
- Debt
- +$32.00B
- Cash
- −$63.00M
Capital structure 69% equity / 31% debt · EV / Revenue 6.01x · EV / EBITDA 17.30x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: KMI stock price at discount vs BMRN $31.40 current versus $50.64 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Implied fair value · at KMI's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: KMI FY 2025 (ended Dec 31, 2025) · BMRN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 69% equity / 31% debt · EV / Revenue 6.01x · EV / EBITDA 17.30x
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
KMI carries the larger enterprise value at $101.86B against $12.07B; BMRN trades on the lower EV / Revenue multiple (3.75x vs 6.01x); KMI on the lower EV / EBITDA (17.30x vs 21.37x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
KINDER MORGAN, INC. · implied price per share
Bear
$1.37
Base
$3.75
Bull
$7.76
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.03x
0.08x
Net debt / EBITDA
Leverage against operating earnings
5.42x
-1.43x
Cash and equivalents
Liquid reserves on the balance sheet
$63.00M
$1.31B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
WILLIAMS COMPANIES, INC.
KMI vs WMB
ONEOK INC /NEW/
KMI vs OKE
ENBRIDGE INC
KMI vs ENB
New Fortress Energy Inc.
KMI vs NFE
VERTEX PHARMACEUTICALS INC / MA
KMI vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
KMI vs ALNY
Sarepta Therapeutics, Inc.
KMI vs SRPT
REGENXBIO Inc.
KMI vs RGNX
IONIS PHARMACEUTICALS INC
KMI vs IONS
PTC THERAPEUTICS, INC.
KMI vs PTCT
$32.00B
$505.32M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.